Scalp injections of botulinum toxin, marketed in South Korea as a treatment for hair loss, have drawn a skeptical response from physicians asked to evaluate the trend — and the gap between clinic marketing and trial data is the story dermatologists should watch.

The trend has surfaced through South Korea's aesthetic clinic market, where botulinum toxin — already among the most widely performed injectable procedures globally — is being offered as a scalp therapy aimed at patients with hair thinning. The framing echoes a hypothesis that has circulated in the literature for years: that relaxing scalp musculature may improve local perfusion and reduce perifollicular tension, theoretically creating better conditions for hair growth.

Doctors interviewed about the trend urged caution. The central problem is evidentiary. Botulinum toxin carries a well-characterized safety and efficacy profile for its approved indications — glabellar lines, hyperhidrosis, and other neuromuscular uses — but hair loss is not among them. Any claim that scalp injections regrow hair or slow shedding rests on a thin and inconsistent body of research, not on the kind of randomized, controlled, adequately powered trials that underpin approved alopecia therapies such as minoxidil or finasteride.

That distinction matters for patient counseling. Androgenetic alopecia and other forms of hair loss are progressive conditions, and patients who spend months on an unproven injectable protocol may delay interventions with established efficacy. Dermatologists reviewing the trend emphasized that patients presenting with hair loss still warrant a proper diagnostic workup — history, trichoscopy, and where indicated, laboratory screening — before any treatment, off-label or otherwise, enters the conversation.

The mechanism proposed by proponents is not new. Published discussions of botulinum toxin in alopecia have speculated about reduced scalp muscle contraction improving blood flow around follicles. Speculation, physicians noted, is not the same as demonstrated clinical benefit. Hair growth endpoints in serious alopecia research are measured with tools such as target-area hair counts and standardized photographic assessment over months of follow-up; the trend now circulating in Seoul's aesthetic market has not been validated against those standards.

There is also a safety conversation. Scalp injection is an off-label use, and while botulinum toxin's general safety record is strong when administered at established doses by trained injectors, off-label protocols carry their own uncertainty — dosing, injection grid, treatment interval, and repeat-exposure risk in the scalp have no consensus guidelines behind them. Physicians weighing in on the trend flagged that marketing language from clinics often blurs the line between cosmetic claims and medical ones, a recurring problem in aesthetic medicine that regulators in several markets have had to police.

For dermatologists, the practical takeaway is straightforward. Patients will increasingly arrive asking about procedures they have seen marketed abroad, particularly from South Korea, whose aesthetic clinic culture drives global trend cycles. The clinical answer is to separate the plausible hypothesis from the proven therapy, to name the evidence gap explicitly, and to redirect patients toward treatments whose efficacy in hair loss is supported by controlled data.

Whether scalp botulinum toxin eventually earns a place in the alopecia armamentarium will depend on properly designed trials with objective hair-density endpoints — until those data exist, physicians interviewed for the trend coverage position it as an interesting hypothesis wrapped in premature marketing.